PUBLISHER: The Business Research Company | PRODUCT CODE: 1764271
PUBLISHER: The Business Research Company | PRODUCT CODE: 1764271
Calcitonin-salmon is a synthetic or recombinant version of the calcitonin hormone, originally sourced from salmon, used as a medication to regulate calcium levels and support bone health. It functions by inhibiting osteoclast activity-the cells that break down bone-thereby slowing bone loss and lowering calcium concentrations in the blood.
The primary forms of calcitonin-salmon include spray and injection. The spray refers to a nasal formulation used to deliver the hormone for treating conditions like osteoporosis. This medication is available in several dosage forms, such as intravenous, subcutaneous, and nasal spray, and is distributed through hospital pharmacies, retail pharmacies, and online platforms. Its applications include treating osteoporosis, Paget's disease of bone, hypercalcemia, myeloma, and other conditions, and it is used across various settings including clinics, pharmacies, and online channels.
The calcitonin salmon market research report is one of a series of new reports from The Business Research Company that provides calcitonin salmon market statistics, including calcitonin salmon industry global market size, regional shares, competitors with a calcitonin salmon market share, calcitonin salmon market segments, market trends and opportunities, and any further data you may need to thrive in the calcitonin salmon industry. This calcitonin salmon market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
The calcitonin salmon market size has grown strongly in recent years. It will grow from $1.21 billion in 2024 to $1.28 billion in 2025 at a compound annual growth rate (CAGR) of 6.0%. The increase during the historical period is due to an aging worldwide population, greater awareness of bone health, a growing number of fractures, improvements in injectable drug formulations, and the expansion of research and development efforts.
The calcitonin salmon market size is expected to see strong growth in the next few years. It will grow to $1.60 billion in 2029 at a compound annual growth rate (CAGR) of 5.7%. The growth expected in the forecast period is driven by increasing healthcare spending, expanded use of hormone-related therapies, peptide drug delivery, enhanced biopharmaceutical research and development, and favorable regulatory approvals. Key trends during this period involve advanced peptide synthesis methods, nanoparticle-based drug delivery systems, sustained-release delivery technologies, recombinant DNA technology, and 3D printing advancements.
The rising incidence of osteoporosis is anticipated to drive the growth of the calcitonin salmon market in the future. Osteoporosis is a medical condition marked by reduced bone density and a higher risk of fractures, mainly affecting older adults, particularly postmenopausal women. The condition is increasing due to longer life expectancy, resulting in a larger aging population vulnerable to bone density loss. Calcitonin salmon aids in managing osteoporosis by inhibiting bone resorption, slowing down bone loss, and helping to maintain bone density in affected individuals. For example, an October 2023 report from the Canadian Medical Association Journal, a peer-reviewed journal based in Canada, stated that over 2 million Canadians live with osteoporosis, and approximately 150 per 100,000 experience hip fractures annually, one of the disease's most severe outcomes. Hence, the growing prevalence of osteoporosis is fueling the expansion of the calcitonin salmon market.
Key companies in the calcitonin salmon market are concentrating on developing innovative solutions, such as calcium regulators, to improve treatment efficacy and patient outcomes. A calcium regulator is a substance or mechanism that helps manage calcium levels in the blood and bones, supporting proper bone formation, maintenance, and metabolic balance. For example, in February 2025, Fresenius Kabi, a pharmaceutical company based in Germany, introduced a synthetic calcitonin salmon injection, USP, to treat symptomatic Paget's disease of the bone and hypercalcemia. This synthetic product is indicated for symptomatic Paget's disease, hypercalcemia, and postmenopausal osteoporosis when other treatments are not suitable. It comes in 400 I.U./2 mL (200 I.U./mL) multi-dose vials and is fully formulated, filled, and packaged in the United States, highlighting Fresenius Kabi's dedication to strengthening domestic pharmaceutical manufacturing and supply chains. The launch of this injection expands the company's generic injectable portfolio, aiming to offer affordable and dependable treatment options for patients.
In April 2022, Hikma Pharmaceuticals plc., a pharmaceutical company based in the UK, acquired Custopharm Inc. for an undisclosed sum. Through this acquisition, Hikma intends to bolster its U.S. injectables business by broadening its product range, improving its research and development capabilities, and speeding up growth in the generic sterile injectable market. Custopharm Inc. is a U.S.-based supplier of complex sterile generic injectable products that include calcitonin salmon.
Major players in the calcitonin salmon market are Sanofi S.A, Boehringer Ingelheim International GmbH, Viatris Inc., Fresenius Kabi AG, Sun Pharmaceutical Industries Limited, Dr. Reddy's Laboratories Limited, Cipla Limited, Hikma Pharmaceuticals plc, Endo International plc, Asahi Kasei Pharma Corporation, Anhui Anke Biotechnology (Group) Co. Ltd., Hybio Pharmaceutical Co. Ltd., Tokyo Chemical Industry Co. Ltd., Santa Cruz Biotechnology Inc., HRV Global Life Sciences Private Limited, AdvaCare Pharma USA LLC, BCN Peptides S.L., Leucadia Pharmaceuticals Inc., Polypeptide Group AB, LKT Laboratories Inc.
North America was the largest region in the calcitonin salmon market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in calcitonin salmon report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.
The countries covered in the calcitonin salmon market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
The calcitonin salmon market consists of sales of nasal spray, auto-injectors, lyophilized powder, nasal gel, and oral spray or tablet. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).
The revenues for a specified geography are consumption values and are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
Calcitonin Salmon Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.
This report focuses on calcitonin salmon market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Where is the largest and fastest growing market for calcitonin salmon ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The calcitonin salmon market global report from the Business Research Company answers all these questions and many more.
The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.
The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.